Patent SG-11201903282T-A (SG)
Title: Immunotherapy methods and compositions involving tryptophan metabolic pathway modulators
Inventor: PORTS MICHAEL
IPC: C07K14/725
Filed: 2017-10-13
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property MD 1101111 0 DOI HIM 011101 0 101111H11 111111111111111 011111110 111 0111111 Organization International Bureau (10) International Publication Number (43) International Publication Date ......0\" WO 2018/071873 A3 19 April 2018 (19.04.2018) WIP0 1 PCT (51) International Patent Classification: UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, A61K 35/17 (2015.01) C12Q 1/26 (2006.01) TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, A61K 45/06 (2006.01) Cl 2N 5/0783 (2010.01) EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, A61K 48/00 (2006.01) G01N 33/574 (2006.01) MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, A61K 31/4245 (2006.01) A61P 35/00 (2006.01) TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, C07K 14/725 (2006.01) KM, ML, MR, NE, SN, TD, TG). (21) International Application Number: PCT/US2017/056680 Declarations under Rule 4.17: — as to the applicant's entitlement to claim the priority of the (22) International Filing Date: earlier application (Rule 4.17(iii)) 13 October 2017 (13.10.2017) Published: (25) Filing Language: English — with international search report (Art. 21(3)) (26) Publication Language: English — before the expiration of the time limit for amending the claims and to be republished in the event of receipt of (30) Priority Data: amendments (Rule 48.2(h)) 62/407,776 13 October 2016 (13.10.2016) US — with sequence listing part of description (Rule 5.2(a)) 62/514,767 02 June 2017 (02.06.2017) US (88) Date of publication of the international search report: (71) Applicant: JUNO THERAPEUTICS, INC. [US/US]; 400 04 October 2018 (04.10.2018) Dexter Ave. N, Suite 1200, Seattle, WA 98109 (US). Inventors: PORTS, Michael; c/o Juno Therapeutics, Inc., 400 Dexter Ave. N, Suite 1200, Seattle, WA 98109 (US). (72) THOMAS, Evan Paul; c/o Juno Therapeutics, Inc., 400 Dexter Ave. N, Suite 1200, Seattle, WA 98109 (US). LEV- ITSKY, Hyam I; c/o Juno Therapeutics, Inc., 400 Dexter Ave. N, Suite 1200, Seattle, WA 98109 (US). Agent: AHN, Sejin et al.; Morrison & Foerster LLP, 12531 (74) High Bluff Drive, Suite 100, San Diego, CA 92130-2040 (US). Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (81) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, (84) M ..! (54) Title: IMMUNOTHERAPY METHODS AND COMPOSITIONS INVOLVING TRYPTOPHAN METABOLIC PATHWAY M MODULATORS ir---- GC (57) : Provided are methods of treatment involving immunotherapy, such as T cell therapy, and administration of a tryptophan - metabolism and/or kynurenine pathway modulator. In some embodiments, the method includes a combination therapy that involves IN administration of engineered T cells, such as chimeric antigen receptor (CAR)-expressing cells, and a tryptophan metabolism and/ 0 --.... or kynurenine pathway modulator, such as an inhibitor of an enzyme. Also provided are engineered cells in which the expression X 1-1 ) of a molecule involved in the kynurenine pathway is modified. Also provided are methods of manufacturing engineered cells, cells, C compositions, methods of administration to subjects, nucleic acids and kits for use in the methods. In some aspects, features of the ei methods and cells provide for increased or improved activity, activity, outcome, function, response, persistence, expansion and/or 0 proliferation of cells for adoptive cell therapy.